stock-exchange-911613_1920

Pharma stocks soar after US midterm elections

November 8, 2018
Business Services, Manufacturing and Production Shares, Stock, Trump, biotech, pharma, stock market

Despite the threat of a bipartisan pricing plan, pharma stocks have soared after the announcement of the results of the …

staphylococcus_aureus_visa

AMR superbugs expected to kill 90,000 Britons in the next 30 years

November 8, 2018
Research and Development AMR, antimicrobial resistance, infectious diseases, spanish flu

Antibiotic resistant superbugs will kill more than 90,000 British people over the next thirty years if action is not taken …

bicycle_therapeutics

Bicycle Therapeutics picks up former Pfizer head as new SVP of Pre-Clinical Development

November 7, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

The Cambridge based biotechnology firm Bicycle therapeutics, has announced former Pfizer head Dr Phil Jeffrey as the company’s new Senior …

787px-prostate_normal_1

Prostate cancer researchers win $2m to explore carboplatin therapy

November 7, 2018
Research and Development Cancer, carboplatin therapy, prostate cancer

The US Department of Defence has awarded a coalition of researchers – made up of the Prostate Cancer Clinical Research …

Former Celgene CEO Bob Hugin loses in US midterm elections

November 7, 2018
Research and Development Bob Hugin, Celgene, Trump, midterms, republican, us politics

Former Celgene CEO Bob Hugin has failed in his bid to win over the people of New Jersey, after voters …

FDA approves BMS’ multiple myeloma combo after it doubles progression-free survival

November 7, 2018
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Empliciti, FDA, US, multiple myeloma, pharma

The FDA has seen fit to approve Bristol-Myers Squibb’s Empliciti (elotuzumab) intravenous injection in combination with pomalidomide and dexamethasone for …

lilly_building_with_american_flag_web

Lilly’s Trulicity reduces major cardiovascular events in “ambitious” trial of type 2 diabetes

November 7, 2018
Research and Development Eli Lilly, Trulicity, cardiovascular events, pharma, type 2 diabetes

Eli Lilly has revealed new data on Trulicity (dulaglutide), showing that glucagon-like peptide-1 (GLP-1) receptor agonist achieved its primary endpoint …

sewage-pipe-polluted-water-3465090_960_720

Very high concentrations of pharmaceuticals found in animals in Australian streams

November 7, 2018
Research and Development Contamination, ecosystems, environment, pharmaceuticals, pollution

More than 60 different pharmaceutical compounds were detected in aquatic invertebrate larvae and riparian predators in six streams near Melbourne, …

uk

UK to push earlier diagnosis and better treatment with 5 AI-driven technology centres

November 6, 2018
Manufacturing and Production, Research and Development AI, Leeds, London, Oxford, UK, glasgow, pharma

The UK’s Business Secretary has announced the introduction of five specialist collaborative centres across the UK which with leverage advanced …

image_credit_-_rafael_matsunaga

Clearside Biomedical shares plummet by 56% after disappointing Phase 3 results

November 6, 2018
Manufacturing and Production

Shares in the US-based pharma firm Clearside Biomedical plummeted on Monday after the company announced disappointing phase III trial results …

450px-official_portrait_of_matt_hancock_crop_2

Health Secretary launches new prevention strategy for NHS

November 6, 2018
Manufacturing and Production Matt Hancock, NHS, health, prevention

British Health Secretary Matt Hancock has said that healthcare should focus on prevention, as he launched a long-term strategy intended …

AstraZeneca sells off three drugs in deal worth $350 million

November 6, 2018
Manufacturing and Production AstraZeneca, asthma, covis, deal, royalties

Anglo-Swedish multinational AstraZeneca has agreed to sell the rights to three asthma and rhinitis drugs in a deal worth $350 …

janssen_latest_logo_on_sign_closer

J&J buy global rights to Yuhan’s lazertinib in deal worth $1.2bn

November 6, 2018
Manufacturing and Production J&J, JJ, NSCLC, Yuhan, deal, lazertinib, south korea

Johnson & Johnson’s Janssen Biotech unit has bought the rights to Yuhan’s third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib in a deal …

horrible_monster_vaccination

Anti-vaxxers: Vaccines in the age of populism

November 6, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing anti vaccine, anti-vaccine, history, medicine, populism, vaccines

Mistrust of the establishment has fuelled anti-vaccine sentiment in recent years, and adherence has waned as a result. Louis Goss …

FDA controversially approves potent opioid up to ten times stronger than fentanyl

November 6, 2018
Sales and Marketing Dsuvia, FDA, US, fentanyl, opioid crisis, opioids, pharma

Despite voices of criticism, the FDA has opted to approve AcelRX’s Dsuvia (sufentanil), an opioid medication said to be five …

5204602349_c87b204860_z

Aurobindo pharma initiate recall of blood pressure drug Ibesartan

November 6, 2018
Manufacturing and Production, Research and Development Aurobindo Pharma, FDA, heart drug, ibesartan, recall

Indian pharma firm Aurobindo Pharma Ltd has initiated a voluntary recall of 22 batches of blood pressure drug Ibesartan, due …

display-dummy-757451_1920

76% of patients no longer experience PTSD a year after MDMA-assisted psychotherapy

November 6, 2018
Manufacturing and Production, Research and Development MDMA, PTSD, mental health, psychotherapy, research

Promising phase II results suggest that MDMA-assisted psychotherapy may be an “innovative, efficacious treatment for posttraumatic stress disorder,” according to …

6813384933_1fb31d73fb_z

HIV drug reduces viral load by 99% within 4 weeks

November 6, 2018
Manufacturing and Production, Research and Development

HIV-drug Gammora may eliminate 99% of the HIV virus within four weeks of treatment, according to the results of a …

The Gateway to Local Adoption Series

Latest content